Oct 13, 2020	PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation
Sep 29, 2020	PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Sep 24, 2020	PMV Pharma Announces Pricing of Initial Public Offering
Sep 08, 2020	PMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel
Aug 03, 2020	PMV Pharma Closes $70 Million in Series D Financing; Dr. Rich Heyman appointed as Chair of the Board of Directors of PMV Pharma